Incorporating the Time Dimension in Receiver Operating Characteristic Curves: A Case Study of Prostate Cancer

Early diagnosis of disease has potential to reduce morbidity and mortality. Biomarkers may be useful for detecting disease at early stages before it becomes clinically ap parent. Prostate-specific antigen (PSA) is one such marker for prostate cancer. This article is concerned with modeling receiver operating characteristic (ROC) curves as sociated with biomarkers at various times prior to the time at which the disease is detected clinically, by two methods. The first models the biomarkers statistically using mixed-effects regression models, and uses parameter estimates from these models to estimate the time-specific ROC curves. The second directly models the ROC curves as a function of time prior to diagnosis and may be implemented using software pack ages with binary regression or generalized linear model routines. The approaches are applied to data from 71 prostate cancer cases and 71 controls who participated in a lung cancer prevention trial. Two biomarkers for prostate cancer were considered: total serum PSA and the ratio of free to total PSA. Not surprisingly, both markers performed better as the interval between PSA measurement and clinical diagnosis decreased. Although the two markers performed similarly eight years prior to diagnosis, it appears that total PSA performed better than the ratio measure at times closer to diagnosis. The area under the ROC curve was consistently greater for total PSA than for the ratio four and two years prior to diagnosis and at the time of diagnosis. Key words: time- dependent ROC curves; biomarkers; diagnosis; prostate-specific antigen. (Med Decis Making 1999; 19:242-251)

[1]  D. Bates,et al.  Newton-Raphson and EM Algorithms for Linear Mixed-Effects Models for Repeated-Measures Data , 1988 .

[2]  H. Carter,et al.  Mixed-effects regression models for studying the natural history of prostate disease. , 1994, Statistics in medicine.

[3]  A S Whittemore,et al.  Prostate-specific antigen as predictor of prostate cancer in black men and white men. , 1995, Journal of the National Cancer Institute.

[4]  Statistical design and monitoring of the Carotene and Retinol Efficacy Trial (CARET). , 1993, Controlled clinical trials.

[5]  M. Benson,et al.  The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. , 1992, The Journal of urology.

[6]  C G Chute,et al.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.

[7]  C B Begg,et al.  A General Regression Methodology for ROC Curve Estimation , 1988, Medical decision making : an international journal of the Society for Medical Decision Making.

[8]  H. Klocker,et al.  Improvement of prostate cancer screening by determination of the ratio free/total PSA in addition to PSA levels , 1997, The Prostate.

[9]  Jerome P. Richie,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.

[10]  Margaret S. Pepe,et al.  A regression modelling framework for receiver operating characteristic curves in medical diagnostic testing , 1997 .

[11]  E. Metter,et al.  Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. , 1996, Urology.

[12]  M S Pepe,et al.  Three approaches to regression analysis of receiver operating characteristic curves for continuous test results. , 1998, Biometrics.

[13]  A W Partin,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.